Welcome, Guest. Please login or register.
November 27, 2020, 09:21:45 pm

Login with username, password and session length


Members
  • Total Members: 6249
  • Latest: Sugar67
Stats
  • Total Posts: 55050
  • Total Topics: 4814
  • Online Today: 69
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 34
Total: 34

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Licogliflozin Lowers Liver Enzymes in People With Fatty Liver Disease  (Read 1322 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 770
    • Hep Mag
An experimental drug that blocks glucose absorption lowered liver enzyme levels, reduced liver fat and led to modest weight loss in people with non-alcoholic steatohepatitis (NASH) in a mid-stage study, according to a presentation at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, this month in Boston.

Non-alcoholic fatty liver disease (NAFLD) and NASH, its more severe form, are responsible for a growing proportion of advanced liver disease. Accumulation of fat in the liver triggers inflammation, which over time can lead to fibrosis (buildup of scar tissue), cirrhosis, liver cancer and the need for a liver transplant. Fatty liver disease is increasingly recognized as a manifestation of metabolic syndrome, a cluster of conditions that include abdominal obesity, elevated blood glucose and abnormal blood fat levels.

There are currently no effective medical therapies for NASH, and management relies on lifestyle changes such as weight loss. Over the past few years, several NAFLD/NASH therapies that appeared promising based on biomarkers in early studies ended up not improving clinical outcomes in larger trials.

Read more...
https://www.hepmag.com/article/licogliflozin-lowers-liver-enzymes-people-fatty-liver-disease

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.